Knowledge sprouting from these results indicate the possibility to reduce tumour angiogenesis and tumor progression in melanoma-bearing patients through injection of autologous EPCs able to deliver the MMP12 anticancer agent into tumor mass, which could inhibit all the uPAR-dependent melanoma progression characteristics. This evidence concerns the gene PLAUR and neoplasm.